Cullinan Therapeutics, Inc. · NASDAQ:CGEM
Cullinan Therapeutics — Cullinan Oncology — Corporate Update (May 2022)
10 slides from Cullinan Therapeutics's corporate update, May 12, 2022
Slide 1: Strategic Partnership With Taiho to Jointly Develop and Commercialize CLN-081 in the U.S.
Exhibit 99.2 Mining for Tomorrow’s Cures Strategic Partnership With Taiho to Jointly Develop and Commercialize CLN-081 in the U.S. May 12, 2022
Slide 2: Important Notice and Disclaimers
Important Notice and Disclaimers This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Cullinan’s beliefs and expectat
Slide 3: Webcast Agenda
Webcast Agenda AGENDA PRESENTERS Nadim Ahmed 1. Introduction Chief Executive Officer Corinne Savill, Ph.D. 2. Collaboration Overview Chief Business Officer 3. Financial Context Jeff Trigilio Chief Financial Officer 4. Strategic Perspective JOINING US FOR Q&A Jeffrey Jones, M.D., MPH, MBA 5. Q&A Prom
Slide 4: CLN-081: Selective EGFR Inhibitor With Best-in-Class Potential for NSCLC Patients with Exon 20 Mutations
CLN-081: Selective EGFR Inhibitor With Best-in-Class Potential for NSCLC Patients with Exon 20 Mutations CLN -081: UNIQUE DESIGN PROPERTIES Distinct chemical scaffold HER2-sparing High selectivity to mutant vs WT EGFR DATA FROM ONGOING PHASE 1 / 2A STUDY (100 mg BID) 41% 15-month 12-month Favorable
Slide 5: Cullinan has Advanced CLN-081 Rapidly, Generating POC and a Strategic Collaboration within ~3 Years
Cullinan has Advanced CLN-081 Rapidly, Generating POC and a Strategic Collaboration within ~3 Years Cullinan Oncology enters Taiho discovery of 1st patient dosed in Initial data reported collaboration with Taiho CLN-081 phase 1/2a study at ASCO START DEC 2019 JUN 2021 APR/MAY 2022 2019 2021 2020 202
Slide 6: Taiho Oncology is the Ideal Partner for CLN-081
Taiho Oncology is the Ideal Partner for CLN-081 • Discovered CLN-081 Unique insight into CLN- • Involved in CLN-081 development through Cullinan Pearl 081’s potential • Molecule well-aligned with Taiho’s strategic focus Robust oncology clinical • Focused on small molecule, molecularly targeted devel
Slide 7: Summary of Terms
Summary of Terms Upfront Payment Milestone Payments $275 million Up to $130 million regulatory-based milestones st nd to Cullinan Oncology on 1 /2 line EGFR exon20 NSCLC Collaboration Profit Sharing U.S. co-development and co- 50/50 share of potential commercialization agreement U.S. profits 7
Slide 8: Transaction Provides Compelling Return on Investment Today and Commercial Participation in Future Upside
Transaction Provides Compelling Return on Investment Today and Commercial Participation in Future Upside PEARL RETURN $425 million in aggregate $295 million to date $42m $20m $275m $130m + 50% of future U.S. development costs and profits Pearl R&D expense Zai Lab upfront Taiho upfront Taiho mileston
Slide 9: Maximizing Shareholder and Patient Value, Commercialization Potential, and Investment
Maximizing Shareholder and Patient Value, Commercialization Potential, and Investment Taiho’s unique insight into CLN-081’s Maximizes value of CLN-081 and supports commercial success potential Retains strategic value to CLN-081 in the most valuable oncology territory and provides potential US 50/50
Slide 10: Q & A
Q & A Nadim Ahmed Corinne Savill, Ph.D. Chief Executive Officer Chief Business Officer Jeffrey Jones, M.D., MPH, MBA Jeff Trigilio Chief Medical Officer Chief Financial Officer 10